Oak Hill Bio - In The Press

Presentations

September 2026

Corporate Presentation

Download Oak Hill Bio's latest corporate presentation.

Oak Hill Bio In The Press

Making Headlines in Advancing Rare Disease Therapies.

Oak Hill Bio to Present at Upcoming Investor Conferences

October 29, 2026

Oak Hill Bio Appoints Joerg Hipp, PhD as Chief Translational Science Officer

October 6, 2026

Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome

July 28, 2026

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

July 27, 2026

FEATURED IN WSJ PRO

Oak Hill Bio Squares Off Against Big Rivals to Find Angelman Treatment

June 15, 2026

Read Full Article [Reprint]

Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome

June 1, 2026

Oak Hill Bio Spotlights Publication Detailing Discovery and Initial Development of Rugonersen in Nucleic Acids Research

September 9, 2025

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

July 11, 2025

Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome

April 15, 2025